Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | TACR1 | P25103 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3518860 | 1.00 | CA1 (0.53) | CA1CA2CA7CA9TSHR | |
| SCHEMBL3522139 | 1.00 | CA1 (0.53) | CA1CA2CA7CA9TSHR | |
| SCHEMBL25037201 | 0.85 | CA1 (0.50) | CA1CA2CA7CA9TSHR | |
| SCHEMBL18630780 | 0.85 | CA1 (0.53) | CA1CA2CA7CA9TSHR | |
| SCHEMBL19713277 | 0.82 | TSHR (0.54) | CA1CA2CA7CA9TSHR | |
| SCHEMBL4498730 | 0.81 | TSHR (0.52) | CA1CA2CA7CA9TSHR | |
| SCHEMBL17789132 | 0.81 | TSHR (0.52) | CA1CA2CA7CA9TSHR | |
| SCHEMBL29230470 | 0.81 | TSHR (0.52) | CA1CA2CA7CA9TSHR | |
| SCHEMBL4498725 | 0.81 | TSHR (0.52) | CA1CA2CA7CA9TSHR | |
| SCHEMBL19726048 | 0.81 | TSHR (0.52) | CA1CA2CA7CA9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117916245-A | Pyrimidine ring compound and preparation method and application thereof | 劲方医药科技(上海)有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-8252810-B2 | Bicycloamine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8252810-B2 | Bicycloamine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8252810-B2 | Bicycloamine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| EP-2241567-A1 | BICYCLOAMINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-10-20 | — | — | EP | disclosed |
| EP-2241567-A1 | BICYCLOAMINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| WO-2009101917-A1 | BICYCLOAMINE DERIVATIVE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-08-20 | — | — | WO | disclosed |
| US-7501516-B2 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2009-03-10 | — | — | US | disclosed |
| EP-1409481-B1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-10-04 | — | — | EP | disclosed |
| US-20050009867-A1 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2005-01-13 | — | — | US | disclosed |
| WO-2003047582-A1 | QUINOLINE DERIVATIVES AS ANTITUMOUR AGENTS | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | SCN1B, KCNJ2, KCNH2 | CA1 2021/4885CA2 883/4885CA7 3048/4885 |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | SCN1B, KCNJ2, KCNH2 | CA1 2021/4885CA2 883/4885CA7 3048/4885 |
| US-20050009867-A1 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ABL1, FLT3, JAK2 | CA1 2953/4885CA2 1497/4885CA7 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.